BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38376187)

  • 1. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an
    Kunz Coyne AJ; Bleick C; Stamper K; Kebriaei R; Bayer AS; Lehman SM; Rybak MJ
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0138823. PubMed ID: 38376187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
    Kunz Coyne AJ; Stamper K; Bleick C; Kebriaei R; Lehman SM; Rybak MJ
    Microbiol Spectr; 2024 Apr; 12(4):e0321223. PubMed ID: 38411110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation
    Kunz Coyne AJ; Stamper K; El Ghali A; Kebriaei R; Biswas B; Wilson M; Deschenes MV; Tran TT; Arias CA; Rybak MJ
    Microbiol Spectr; 2023 Aug; 11(4):e0034023. PubMed ID: 37338375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections
    Kebriaei R; Lev KL; Shah RM; Stamper KC; Holger DJ; Morrisette T; Kunz Coyne AJ; Lehman SM; Rybak MJ
    Microbiol Spectr; 2022 Apr; 10(2):e0041122. PubMed ID: 35348366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus.
    Tsai CE; Yang CJ; Chuang YC; Wang JT; Sheng WH; Chen YC; Chang SC
    Int J Infect Dis; 2022 Sep; 122():230-236. PubMed ID: 35640827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
    Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant
    Kunz Coyne AJ; Stamper K; Kebriaei R; Holger DJ; El Ghali A; Morrisette T; Biswas B; Wilson M; Deschenes MV; Canfield GS; Duerkop BA; Arias CA; Rybak MJ
    Antibiotics (Basel); 2022 Aug; 11(9):. PubMed ID: 36139953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
    Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT
    Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections.
    Eliazar J; Johnson T; Chbib C
    Curr Rev Clin Exp Pharmacol; 2021; 16(4):296-299. PubMed ID: 33423652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Steed ME; Werth BJ; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.
    Barber KE; Werth BJ; Rybak MJ
    J Antimicrob Chemother; 2015 Feb; 70(2):505-9. PubMed ID: 25246437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations about the Use of a Loading Dose of Daptomycin in a Neutropenic Murine Thigh Infection Model with Methicillin-Resistant Staphylococcus aureus Infection.
    Kato H; Hagihara M; Murakami E; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Uno B; Mikamo H
    Chemotherapy; 2018; 63(1):13-19. PubMed ID: 29130946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.